A βγ dimer derived from G13 transduces the angiotensin AT1 receptor signal to stimulation of Ca2+ channels in rat portal vein myocytes
J. Biol. Chem.. 1997-09-12; 272(37): 23180-23185
Lire sur PubMed
1. Expert Opin Ther Pat. 2018 Jul;28(7):551-560. doi: 10.1080/13543776.2018.1495708.
HIV cure: global overview of bNAbs’ patents and related scientific publications.
Possas C(1), Antunes AMS(2)(3), Lins Mendes FM(2), Veloso V(4), Martins RM(1),
(1)a Bio-Manguinhos , Oswaldo Cruz Foundation (FIOCRUZ) , Rio de Janeiro ,
(2)b School of Chemistry , Federal University of Rio de Janeiro (EQ/UFRJ) , Rio
de Janeiro , Brazil.
(3)c c-academy, National Institute of Industrial Property (INPI) , Rio de Janeiro
(4)d Evandro Chagas National Institute of Infectology (INI/FIOCRUZ), Oswaldo Cruz
Foundation , Rio de Janeiro , Brazil.
INTRODUCTION: This article provides a global overview of patent deposits for
broadly neutralizing antibodies (bNAbs), which have emerged as a key strategy for
HIV cure and future HIV vaccines. Scientific and technological barriers to the
discovery of an effective HIV vaccine in the last 40 years have raised concerns
on the potential for relevant advances in this area. Nevertheless, recent
breakthrough studies have identified novel immune pathways for new innovative HIV
vaccine and HIV cure strategies. Areas covered: In our patent study, we have
identified in a global scale, in the last decade, a sharp increase in the number
of bNAbs’ patent deposits related to HIV prevention and treatment strategies,
reaching 90 bNAbs in 2017, protected by 184 different patent deposits. Refining
our patent search to the different stages of bNAbs’ development has also allowed
us to identify 12 of them already at clinical stage of research (VRC01, 10E8,
3BNC117, 10-1074, 2G12, 2F5, KD-247, 4E10, PG9, PGDM1400, PGT121, and VRC07). We
describe these recent breakthroughs and discuss the prospects and limitations of
these novel strategies. Expert opinion: Our results indicate the intellectual
property outcomes of a scientific revolution in this field, expressing innovative
modifications in antibodies to increase their potency and half-life, which have
resulted in extremely potent antibodies that could provide novel preventive and
therapeutic HIV strategies.
PMID: 29962249 [Indexed for MEDLINE]